According to the outlet, New York-based Pfizer sold over-the-counter ranitidine drugs also known as Zantac from 1998 through 2006. In 2019, a small laboratory in Connecticut found that ranitidine ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been ... early 1980s and sold it as a prescription and over-the-counter (OTC) product for indications like heartburn ...

Ranitidine products are used to reduce the production of stomach acid in patients with conditions such as heartburn and stomach ulcers. They are available over-the-counter and on prescription.

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

Shares in GSK opened 1.9-percent lower in London following the results update. Over-the-counter treatment Zantac, known also by its non-commercial name ranitidine, was manufactured by several ...

pulling all prescription and over-the-counter heartburn drugs containing ranitidine from the market on April 1, 2020. GSK continues to deny any liability in these cases saying “…The scientific ...

Angela Valadez, 89, used over-the-counter Zantac religiously for 18 years before being diagnosed with colorectal cancer, she said in her lawsuit. She’s now seeking at least $640-million in ...

as well as GSK — to pull Zantac off the market over mounting concerns that its active ingredient, ranitidine, could degrade into an organic chemical called NDMA, over time or when exposed to heat.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

The four in the recall are made by GlaxoSmithKline (GSK). Over-the-counter products (Zantac 75 Relief (PL 02855/0081 [GSL]) and Zantac 75 Tablets (PL 02855/0082 [P]), which people can buy in ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.